145 related articles for article (PubMed ID: 27461600)
1. SiRNA and epigenetic aberrations in ovarian cancer.
Mirzaei H; Yazdi F; Salehi R; Mirzaei HR
J Cancer Res Ther; 2016; 12(2):498-508. PubMed ID: 27461600
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics in ovarian cancer.
Seeber LM; van Diest PJ
Methods Mol Biol; 2012; 863():253-69. PubMed ID: 22359298
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation of cancer-associated genes in ovarian cancer.
Kwon MJ; Shin YK
Int J Mol Sci; 2011 Jan; 12(2):983-1008. PubMed ID: 21541038
[TBL] [Abstract][Full Text] [Related]
4. Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.
Leong CT; Ong CK; Tay SK; Huynh H
Oncogene; 2007 Feb; 26(6):870-80. PubMed ID: 16862170
[TBL] [Abstract][Full Text] [Related]
5. siRNA delivery for the treatment of ovarian cancer.
Goldberg MS
Methods; 2013 Sep; 63(2):95-100. PubMed ID: 23403216
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
[TBL] [Abstract][Full Text] [Related]
8. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation.
Leu YW; Rahmatpanah F; Shi H; Wei SH; Liu JC; Yan PS; Huang TH
Cancer Res; 2003 Oct; 63(19):6110-5. PubMed ID: 14559786
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of targets for ovarian cancer gene silencing therapy: in vitro and in vivo approaches.
Malek A; Tchernitsa O
Methods Mol Biol; 2010; 623():423-36. PubMed ID: 20217567
[TBL] [Abstract][Full Text] [Related]
10. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
11. Silencing of cyclooxygenase-2 inhibits the growth, invasion and migration of ovarian cancer cells.
Lin Y; Cui M; Xu T; Yu W; Zhang L
Mol Med Rep; 2014 Jun; 9(6):2499-504. PubMed ID: 24718658
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.
Barton CA; Hacker NF; Clark SJ; O'Brien PM
Gynecol Oncol; 2008 Apr; 109(1):129-39. PubMed ID: 18234305
[TBL] [Abstract][Full Text] [Related]
13. Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells.
Bapat SA; Jin V; Berry N; Balch C; Sharma N; Kurrey N; Zhang S; Fang F; Lan X; Li M; Kennedy B; Bigsby RM; Huang TH; Nephew KP
Epigenetics; 2010; 5(8):716-29. PubMed ID: 20676026
[TBL] [Abstract][Full Text] [Related]
14. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
[TBL] [Abstract][Full Text] [Related]
15. [Vector construction and silencing effect of Edg4 gene targeted small interfering RNA in ovarian cancer cell line].
Qiao YH; Li LX; Guo RX; Zhou W; Wang M; Zhang XY; Zhang JH; Zhao XL; Zhang MZ; Zhao GQ
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):765-9. PubMed ID: 18307905
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.
Taniguchi H; Yamamoto H; Akutsu N; Nosho K; Adachi Y; Imai K; Shinomura Y
J Pathol; 2007 Oct; 213(2):131-9. PubMed ID: 17724792
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
[TBL] [Abstract][Full Text] [Related]
18. Minireview: epigenetic changes in ovarian cancer.
Balch C; Fang F; Matei DE; Huang TH; Nephew KP
Endocrinology; 2009 Sep; 150(9):4003-11. PubMed ID: 19574400
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
Singh AK; Chandra N; Bapat SA
Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
[TBL] [Abstract][Full Text] [Related]
20. siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer.
Halbur C; Choudhury N; Chen M; Kim JH; Chung EJ
SLAS Technol; 2019 Apr; 24(2):137-150. PubMed ID: 30616494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
